SmallCaps
ASX:PCKHealth Care Equipment & ServicesHealth Care Technology

PainChek Ltd

$0.098
$0.001 (1.01%)
Day Range
$0.098 – $0.100
52 Week Range
$0.095 – $1.050
Volume
85.48K
Avg Volume (10D)
97.72K
Market Cap
$20.48M

Price Chart

OHLC · volume · moving averages

$0.098-$0.082 (-45.56%)over 6M
Hi$0.225Lo$0.095
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.100
Previous Close
$0.099
Day High
$0.100
Day Low
$0.098
52 Week High
$1.050
52 Week Low
$0.095

Valuation

Fundamental multiples

Market Cap
20.48M
Shares Outstanding
209.01M
Price to Book
8.31

Trading Activity

Volume & order book

Volume
85.48K
Value Traded
8.43K
Bid
$0.097 × 74,000
Ask
$0.100 × 159,400

Performance

Returns across timeframes

1 Day
-1.00%
5 Day
0.00%
13 Week
-23.85%
52 Week
-74.62%
YTD
-65.86%

Technical Indicators

Momentum & moving averages

RSI (14)
43.54
50-Day SMA
$0.105
200-Day SMA
$0.190

— From the desk

Latest News

PainChek Inks Landmark 20,000-Bed North America Deployment with Sabra Health Care REIT
Biotechnology

PainChek Inks Landmark 20,000-Bed North America Deployment with Sabra Health Care REIT

PainChek inks landmark 20,000-bed North American deployment with Sabra Health Care REIT across 329 facilities, funding beds at $55-75/bed/yr.

PainChek partners with Eldermark Software to expand US market for smartphone pain assessment app
Technology

PainChek partners with Eldermark Software to expand US market for smartphone pain assessment app

Smartphone pain assessment app developer PainChek (ASX: PCK) has signed a new reseller and integration agreement with Minneapolis-based assisted living provider Eldermark Software to help expand its US market reach. Under the terms of the 12-month rolling agreement, Eldermark will act as a non-exclusive reseller of PainChek’s Adult phone app targeting the US long-term residential […]

PainChek prepares FDA De Novo submission for smartphone app following successful US clinical study
Technology

PainChek prepares FDA De Novo submission for smartphone app following successful US clinical study

PainChek (ASX: PCK) has announced positive outcomes from a US clinical validation study that will allow the company to progress with a Food and Drug Administration (FDA) De Novo submission for its Adult smartphone app. The study recruited 105 nursing home residents at five sites in Iowa and New York, who were assessed for pain […]

Residential aged care sector drives strong quarterly results for PainChek
Technology

Residential aged care sector drives strong quarterly results for PainChek

Australian medical device company PainChek (ASX: PCK) has reported a strong performance for the March quarter with much of its growth being driven by the country’s residential aged care sector. PainChek’s smartphone-based pain assessment technology was contracted to 49,811 residential aged care and dementia-specific beds during the quarter, representing a 56% increase on the 32,023 […]